You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康哲藥業(00867.HK)與Cosmo就創新專利藥物Lumeblue(亞甲藍MMX)達成授權合約
格隆匯 12-04 07:44

格隆匯 12 月 4日丨康哲藥業(00867.HK)發佈公告,集團通過其全資附屬公司於2020年12月3日與Cosmo Technologies Ltd.(“Cosmo”),一家專注於開發和商業化胃腸道疾病相關產品的專業製藥公司,就創新專利藥物Methylthioninium Chloride Cosmo及其延伸線訂立授權、合作與經銷合約。產品目前包括已被歐洲藥品管理局(EMA)批准以Lumeblue的商品名在歐洲商業化的藥物,用於在結腸鏡檢查過程中檢測病變。基於Cosmo的專有創新技術,該口服用於診斷的藥物已在臨牀上證明了其對結直腸癌/癌前病變診斷敏感性的提高。

根據授權合約,集團通過其全資附屬公司將獲得在中國大陸、中國香港、中國澳門和中國台灣開發及商業化產品並在商業化中使用產品商標的獨家授權權利。授權合約期限為授權合約生效之日起至下述情況的較晚者:(i)產品於區域內首次商業化銷售起算第二十週年,或(ii)Cosmo產品專利的最後失效日期。上述期限屆滿後,根據授權合約約定的特定條件,授權合約可在此後以每三年為一個區間續期。通過此次合作,集團消化系統產品將在產品於區域上市後得以豐富及擴張。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account